|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 495/04 | |
| A61K 31/519 | |||
| A61P 37/00 | |||
| A61P 35/00 | |||
| A61P 11/00 |
| (11) | Patento numeris | 3274352 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 16710764.8 |
| Europos patento paraiškos padavimo data | 2016-03-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-01-31 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-01-02 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2016/056106 |
| Data | 2016-03-21 |
| (87) | Numeris | WO 2016/150901 |
| Data | 2016-09-29 |
| (30) | Numeris | Data | Šalis |
| 15161165 | 2015-03-26 | EP | |
| 15174566 | 2015-06-30 | EP | |
| 15184732 | 2015-09-10 | EP |
| (72) |
HÄRTER, Michael, DE
KOSEMUND, Dirk, DE
DELBECK, Martina, DE
KALTHOF, Bernd, DE
WASNAIRE, Pierre, DE
SÜSSMEIER, Frank, DE
LUSTIG, Klemens, DE
|
| (73) |
Bayer Pharma Aktiengesellschaft,
Müllerstrasse 178, 13353 Berlin,
DE
|
| (54) | HETEROCYCLYLMETHYL-THIENOURACILE ALS ANTAGONISTEN DES ADENOSIN-A2B-REZEPTORS |
| HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR |